Atorvastatin in the secondary prevention of cardiovascular diseases
Clinical manifestations of the atherosclerotic process are leading causes of mortality, morbidity and disability in the adult population of the developed countries all over the world. Many years of research have established a clear relationship between the risk of cardiovascular disease and high cho...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2014-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/666 |
id |
doaj-1b128c074a82492bb42f0cb82a4ef93c |
---|---|
record_format |
Article |
spelling |
doaj-1b128c074a82492bb42f0cb82a4ef93c2021-07-28T13:29:17ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902014-12-01011333710.21518/2079-701X-2014-11-33-37666Atorvastatin in the secondary prevention of cardiovascular diseasesN. A. Vaulin0City Hospital №29 named after N.E. BaumanClinical manifestations of the atherosclerotic process are leading causes of mortality, morbidity and disability in the adult population of the developed countries all over the world. Many years of research have established a clear relationship between the risk of cardiovascular disease and high cholesterol level. Numerous global epidemiological studies, such as, for example, the Framingham Heart Study [1] and INTERHEART [2], provided solid evidence confirming that statement. Moreover, randomized clinical trials of lipid-lowering interventions over the past 10-15 years demonstrate that greater cholesterol reduction is associated with a significant decrease in the risk of complications.https://www.med-sovet.pro/jour/article/view/666сердечно-сосудистые заболеванияпрофилактикастатиныаторвастатинcardiovascular diseasepreventionstatinsatorvastatin |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
N. A. Vaulin |
spellingShingle |
N. A. Vaulin Atorvastatin in the secondary prevention of cardiovascular diseases Медицинский совет сердечно-сосудистые заболевания профилактика статины аторвастатин cardiovascular disease prevention statins atorvastatin |
author_facet |
N. A. Vaulin |
author_sort |
N. A. Vaulin |
title |
Atorvastatin in the secondary prevention of cardiovascular diseases |
title_short |
Atorvastatin in the secondary prevention of cardiovascular diseases |
title_full |
Atorvastatin in the secondary prevention of cardiovascular diseases |
title_fullStr |
Atorvastatin in the secondary prevention of cardiovascular diseases |
title_full_unstemmed |
Atorvastatin in the secondary prevention of cardiovascular diseases |
title_sort |
atorvastatin in the secondary prevention of cardiovascular diseases |
publisher |
Remedium Group LLC |
series |
Медицинский совет |
issn |
2079-701X 2658-5790 |
publishDate |
2014-12-01 |
description |
Clinical manifestations of the atherosclerotic process are leading causes of mortality, morbidity and disability in the adult population of the developed countries all over the world. Many years of research have established a clear relationship between the risk of cardiovascular disease and high cholesterol level. Numerous global epidemiological studies, such as, for example, the Framingham Heart Study [1] and INTERHEART [2], provided solid evidence confirming that statement. Moreover, randomized clinical trials of lipid-lowering interventions over the past 10-15 years demonstrate that greater cholesterol reduction is associated with a significant decrease in the risk of complications. |
topic |
сердечно-сосудистые заболевания профилактика статины аторвастатин cardiovascular disease prevention statins atorvastatin |
url |
https://www.med-sovet.pro/jour/article/view/666 |
work_keys_str_mv |
AT navaulin atorvastatininthesecondarypreventionofcardiovasculardiseases |
_version_ |
1721274566907527168 |